Long-term Therapy
VANTAS is a GnRH agonist therapy that may be appropriate for patients with advanced prostate cancer. With only one administration per year, your patients can receive effective and continuous suppression of testosterone levels. VANTAS has a demonstrated safety and tolerability profile in clinical trials.1-4
Choose the clinical data you'd like to read from the links below.
- See the facts about VANTAS and GnRH agonist therapy
- VANTAS was shown to provide effective testosterone suppression and reduction in PSA levels
- Once-yearly VANTAS has a demonstrated safety and tolerability profile over 104 weeks in a clinical trial
- In clinical trials, the most common adverse reactions were hot flashes, fatigue, and implant site reaction. During post-marketing surveillance, rare cases of pituitary apoplexy have been reported after the administration of GnRH agonists. Post-marketing surveillance has identified a rare instance of a drug induced liver injury potentially associated with VANTAS.
- Watch step-by-step video guides for the recommended insertion and removal of the VANTAS implant
